|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 163.8 USD | +1.85% |
|
+2.61% | +5.69% |
| Apr. 30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
| Apr. 29 | Health Care Up on Growth Optimism -- Health Care Roundup | DJ |
April 23 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday alerted clinicians about risks of counterfeit versions of AbbVie's Botox that were given to consumers for cosmetic purposes in multiple states.
The CDC, U.S. Food and Drug Administration (FDA) and state and local partners are investigating reports of harmful reactions among people who received injections of counterfeit Botox. (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.69% | 290B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B | |
| +1.72% | 123B |
ABBVIE INC. 
